AstraZeneca Asthma Drug Helps Patients With Rare Immune Disease

AstraZeneca Plc’s new asthma drug helps patients with a rare, debilitating immune disease that damages vital organs, offering the possibility of an effective treatment for the disorder, a small study found.

In a study of 20 people that lasted almost a year, 14 had sustained responses to injections of Astra’s Fasenra, according to results published Wednesday in the New England Journal of Medicine. Patients with severe skin rashes, lung disease and blood-vessel inflammation as a result of the rare disorder saw their conditions vastly improve and were able to stop taking harsh treatments such as corticosteroids and immunosuppressants, said Mark ...